Distinct relationship of antitumor activity of lenvatinib (LEN) and sorafenib (SOR) to FGF21 expression levels in preclinical hepatocellular carcinoma (HCC) models

被引：0
|
作者：
Miyano, S. Watanabe [1 ]
Taisuke, H. [1 ]
Ito, J. [1 ]
Kodama, K. [1 ]
Watanabe, H. [1 ]
Takase, K. [1 ]
Matsui, J. [2 ]
Funahashi, Y. [1 ]
Nomoto, K. [2 ]
机构：
[1] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki, Japan
[2] Eisai Inc, Oncol Business Grp, Woodcliff Lake, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
94 (PB-045
引用
收藏
页码：E39 / E39
页数：1
相关论文
共 11 条
  • [1] Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
    Matsuki, Masahiro
    Yamamoto, Yuji
    Hoshi, Taisuke
    Kimura, Takayuki
    Funahashi, Yasuhiro
    Matsui, Junji
    CANCER RESEARCH, 2017, 77
  • [2] Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models
    Hoshi, Taisuke
    Matsuki, Masahiro
    Yamamoto, Yuji
    Minoshima, Yukinori
    Matsui, Junji
    Funahashi, Yasuhiro
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [3] Health-related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)
    Vogel, Arndt
    Qin, Shukui
    Kudo, Masatoshi
    Hudgens, Stacie
    Yamashita, Tatsuya
    Yoon, Jung-Hwan
    Fartoux, Laetitia
    Simon, Krzysztof
    Lopez, Carlos L.
    Sung, Max
    Dutcus, Corina E.
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Grunow, Nathan
    Meier, Genevieve
    Breder, Valeriy
    HEPATOLOGY, 2017, 66 : 734A - 734A
  • [4] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND DISEASE SYMPTOMS IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH LENVATINIB (LEN) OR SORAFENIB (SOR)
    Vogel, A.
    Qin, S.
    Kudo, M.
    Hudgens, S.
    Yamashita, T.
    Yoon, J.
    Fartoux, L.
    Simon, K.
    Lopez, C.
    Sung, M.
    Dutcus, C.
    Kraljevic, S.
    Tamai, T.
    Grunow, N.
    Meier, G.
    Breder, V
    VALUE IN HEALTH, 2017, 20 (09) : A454 - A455
  • [5] Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)
    Vogel, A.
    Qin, S.
    Kudo, M.
    Hudgens, S.
    Yamashita, T.
    Yoon, J-H.
    Fartoux, L.
    Simon, K.
    Lopez Lopez, C.
    Sung, M.
    Dutcus, C.
    Kraljevic, S.
    Tamai, T.
    Grunow, N.
    Meier, G.
    Breder, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Antitumor and antiangiogenic activities of lenvatinib (LEN) in mouse xenograft models of VEGF-induced hypervascular human hepatocellular carcinoma (HCC)
    Adachi, Y.
    Matsuki, M.
    Watanabe, H.
    Takase, K.
    Dairiki, R.
    Tabata, K.
    Kodama, K.
    Matsui, J.
    Funahashi, Y.
    Nomoto, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E127 - E127
  • [7] Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
    Lim, Chloe
    Amaro, Carla Pires
    Ding, Philip Q.
    Cheung, Winson Y.
    Tam, Vincent C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 553 - 553
  • [8] Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
    Edeline, Julien
    Merle, Philippe
    Fang, Weijia
    Assenat, Eric
    Pan, Hongming
    Rimassa, Lorenza
    Li, Zhiwei
    Blanc, Jean-Frederic
    Yen, Chia-Jui
    Ross, Paul J.
    Hu, Sheng
    Zhang, Tao
    Tran, Albert
    Shao, Guoliang
    Bouattour, Mohamed
    Chen, Yajin
    Wu, John
    Li, Bai
    Chica-Duque, Sandra
    Ren, Zhenggang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
    Edeline, Julien
    Merle, Philippe
    Fang, Weijia
    Assenat, Eric
    Pan, Hongming
    Rimassa, Lorenza
    Li, Zhiwei
    Blanc, Jean-Frederic
    Yen, Chia-Jui
    Ross, Paul J.
    Hu, Sheng
    Zhang, Tao
    Tran, Albert
    Shao, Guoliang
    Bouattour, Mohamed
    Chen, Yajin
    Wu, John
    Li, Vincent
    Chica-Duque, Sandra
    Ren, Zhenggang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma
    Kohya, Risako
    Suda, Goki
    Ohara, Masatsugu
    Sasaki, Takashi
    Yoda, Tomoka
    Sakurai, Naofumi
    Yoshida, Sonoe
    Fu, Qingjie
    Yang, Zijian
    Hosoda, Shunichi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Suzuki, Kazuharu
    Kawagishi, Naoki
    Nakai, Masato
    Sho, Takuya
    Natsuizaka, Mitsuteru
    Ogawa, Koji
    Sakamoto, Naoya
    CANCERS, 2023, 15 (12)
12